Código 300339 (Harmonized System 2012 by 6 digits)
2024: US$7.94M, Total Trade Exchange
2024: US$13.5k, International Sales
2024: US$7.93M, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) was US$7.94M.
In 2009, the states with the most international sales in Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were Ciudad de México (US$48.7k).
The states with the most international purchases in 2024 were Jalisco (US$6.82M) and Ciudad de México (US$1.11M).
In 2009, the main commercial destinations of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were Italy (US$18.6k), United States (US$15.1k), Dominican Republic (US$11.7k), and Argentina (US$3.27k).
The main commercial origins of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) in 2024 were China (US$4.27M), Italy (US$2.63M), Argentina (US$642k), South Korea (US$381k), and United States (US$10.8k).
In the global context, the main exporting countries of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) in 2022 were Denmark (US$196M), United States (US$146M), and Poland (US$89.4M). In the same year, the main importing countries of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were Denmark (US$171M), United States (US$134M), and India (US$81.6M).
US$7.94M, Total Trade Exchange (2024)
In 2024, the total trade exchange of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) in Mexico (including international purchases and sales) was US$7.94M.
The visualizations show the net balance of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
March, 2025: US$676k, International Purchases
In March 2025, international sales of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were US$0, while international purchases reached US$676k. The above results in a trade balance of -US$676k.
Ciudad de México: US$48.7k, State with the Most International Sales (2009)
Italy: US$18.6k, Main commercial destination (2009)
In 2009, the states with the highest international sales in Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were Ciudad de México (US$48.7k).
In 2009, the countries with the most international purchases from Mexico were Italy (US$18.6k), United States (US$15.1k), Dominican Republic (US$11.7k), and Argentina (US$3.27k).
Jalisco: US$6.82M, State with the Most International Purchases (2024)
China: US$4.27M, Main Commercial Origin (2024)
In 2024, the states with the highest international in Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were Jalisco (US$6.82M) and Ciudad de México (US$1.11M).
The countries with the most international sales to Mexico in 2024 were China (US$4.27M), Italy (US$2.63M), Argentina (US$642k), South Korea (US$381k), and United States (US$10.8k).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin). On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin). In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were Denmark (US$196M), United States (US$146M), and Poland (US$89.4M). In the same year, the main importing countries for Medicaments Containing Hormones or Steroids Used as Hormones, not Containing Antibiotics, not in Measured Doses or put up for Sale to the Retail (Exc. Containing Insulin) were Denmark (US$171M), United States (US$134M), and India (US$81.6M).